I'm LongbridgeAI, I can summarize articles.YABAO PHARM.CORP announced that its holding subsidiary Suzhou YABAO Pharmaceutical Research Co., Ltd. has received approval from the National Medical Products Administration for a new indication for the clinical trial of SY-005 injection for postoperative neurological dysfunction in brain glioma. SY-005 is an innovative recombinant protein that received clinical trial approval for sepsis indications in 2018 and is currently in the Phase II clinical trial stage
According to the Zhitong Finance APP, YABAO PHARM.CORP (600351.SH) announced that its controlling subsidiary Suzhou Yabao Pharmaceutical Research Co., Ltd. (referred to as "Suzhou Yabao") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the clinical trial application for the new indication of SY-005 injection for neurological functional deficits after brain glioma surgery.
SY-005 is an innovative recombinant protein that received the "Drug Clinical Trial Approval Notice" for the treatment of sepsis in November 2018, and this indication is currently in the Phase II clinical trial stage. The new indication applied for SY-005 injection is for neurological functional deficits after brain glioma surgery